Skip to content
Research Article Open access CC BY 4.0

Atypical Antipsychotic Prevents and Reverses Negative Symptoms in Models of Schizophrenia

Nagi F. Idris

International Neuropsychiatric Disease Journal · pp. 1–10 · Published 28 Jun 2017

10.9734/INDJ/2017/34161

Abstract

Introduction: Negative symptoms associated with cognitive impairment as a core symptom of schizophrenia with significant poor quality of life and remain an unmet clinical need. Administration of N-methyl-D-aspartate (NMDA) receptor antagonists in rodents has been proposed as an animal model of negative symptoms in this disorder. Evidence from both animal models and human studies implicates a dysfunction of NMDA receptor function may attribute to pathophysiology of schizophrenia. Objectives: This study was undertaken to investigate the ability of sub-chronic co-administration of clozapine and haloperidol to both prevent and attenuate the social deficits induced by the NMDA receptor antagonist, phencyclidine (PCP) in the social interaction tasks. Methods: In the first test, female Sprague-Dawley rats were treated with saline, clozapine 5.0 mg/kg or haloperidol 0.05 mg/kg, 30 min later followed by either saline or PCP 2.0 mg/kg twice daily for 7 days, followed by 7 days drug free before tested in social interaction tasks. For the second test, female Sprague-Dawley rats received either vehicle or PCP 2.0 mg/kg for 7 days followed by 7 days drug free. Then rats received clozapine 5.0 mg/kg, haloperidol 0.05 mg/kg or vehicle twice daily for 7 days and were tested 120 min following the last dose of antipsychotic in social interaction tasks. Results: PCP treatment produced a significantly reduced social behaviours and that effect significantly prevented and improved by clozapine, but not haloperidol. Conclusions: These results suggest that antagonism of the consequences of reduced NMDA receptor function could contribute to the superior efficacy of atypical antipsychotic agents in improving negative symptoms in schizophrenia. These negative symptoms impairment likely reflect clinically relevant and can be used to evaluate the antipsychotic potential of new compounds on cognitive symptoms of schizophrenia.

PCP negative symptoms schizophrenia NMDA receptors rats

References (31)

  1. 1 Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex [DOI]
  2. 2 Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial [DOI]
  3. 3 NMDA receptor hypofunction model of schizophrenia [DOI]
  4. 4 The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia [DOI]
  5. 5 Predictive Values of Neurocognition and Negative Symptoms on Functional Outcome in Schizophrenia: A Longitudinal First-Episode Study With 7-Year Follow-Up [DOI]
  6. 6 A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia [DOI]
  7. 7 Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia [DOI]
  8. 8 Negative Symptoms in Schizophrenia: Avolition and Occam's Razor [DOI]
  9. 9 Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism [DOI]
  10. 10 Serotonin model of schizophrenia: emerging role of glutamate mechanisms [DOI]
  11. 11 Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine [DOI]
  12. 12 Subchronic Phencyclidine Administration Reduces Mesoprefrontal Dopamine Utilization and Impairs Prefrontal Cortical-Dependent Cognition in the Rat [DOI]
  13. 13 Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin [DOI]
  14. 14 Dopaminergic Terminals in the Rat Cortex [DOI]
  15. 15 Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation [DOI]
  16. 16 M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats [DOI]
  17. 17 The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm [DOI]
  18. 18 Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex [DOI]
  19. 19 Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat [DOI]
  20. 20 Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine [DOI]
  21. 21 A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats [DOI]
  22. 22 Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors [DOI]
  23. 23 Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis [DOI]
  24. 24 Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat [DOI]
  25. 25 Effects of clozapine on cognitive function in schizophrenia.
  26. 26 Impaired Inhibition of Conditioned Responses Produced by Subchronic Administration of Phencyclidine to Rats [DOI]
  27. 27 MK-801-induced hyperlocomotion: Differential effects of M100907, SDZ PSD 958 and raclopride [DOI]
  28. 28 Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic–pituitary–adrenal axis activity: interaction with serotonergic systems [DOI]
  29. 29 M100907 and Clozapine, but not Haloperidol or Raclopride, Prevent Phencyclidine-Induced Blockade of NMDA Responses in Pyramidal Neurons of the Rat Medial Prefrontal Cortical Slice [DOI]
  30. 30 Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms [DOI]
  31. 31 [Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP].

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

9

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.